Lower GI 2017

Prognostic Significance of CRM involvement after Chemo-Radiotherapy for LARC

CRM 2yr LR

2yr OS

5y OS

5yr DFS

5yr LR free survival

5yr DM free survival

Gosens et al 2007 n = 201 cT3/T4 Rullier et al 2010 n = 292 uT3/T4

Neg 8% 80%

Pos

43%* 58%*

Neg

80%

Pos

30%*

Kim et al 2009 n = 420 cT3/T4

Neg

78%

Pos

44%*

Trakarnsanga et al 2013 n = 563 cT3/T4

> 1mm

98 %

< 1mm

66 %

> 2mm

78 %

< 2mm

41 %*

* = significant in multivariate analysis